US EPA

6324941 

Journal Article 

Role of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in the management of hepatocellular carcinoma: consensus at the Symposium of the 48th Annual Meeting of the Liver Cancer Study Group of Japan 

Kudo, M; Matsui, O; Sakamoto, M; Kitao, A; Kim, T; Ariizumi, S; Ichikawa, T; Kobayashi, S; Imai, Y; Izumi, N; Fujinaga, Y; Arii, S 

2013 

1 

Oncology: International Journal of Cancer Research and Treatment
ISSN: 0030-2414
EISSN: 1423-0232 

84 Suppl 1 

21-27 

English 

23428854 

10.1159/000345885 

WOS:000315323300004 

We summarize here the consensus reached at the Symposium of the 48th Annual Meeting of the Liver Cancer Study Group of Japan held in Kanazawa on July 20th and 21st, 2012, on the role of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (EOB-MRI) in the management of hepatocellular carcinoma (HCC). Currently, dynamic CT is the first choice of imaging modality when HCC is suspected. EOB-MRI is useful for differentiation and definitive diagnosis of HCC when dynamic CT/MRI does not show conclusive findings for HCC. In addition, contrast- enhanced ultrasound with Sonazoid is useful for making a decision on whether or not to treat a hypovascular lesion <1 cm when the nodules are shown with low intensity in the hepatocyte phase of EOB-MRI. Furthermore, EOB-MRI should be performed in selected cases of HCC ultrahigh-risk groups every 3-4 months, or EOB-MRI should be performed at least once at the first visit in all HCC ultrahigh-risk groups. 

Hepatocellular carcinoma; EOB-MRI; Expert consensus